Form 4: Director Victor Sandor Receives Prelude Therapeutics Grant

Director Victor Sandor was granted 38,000 stock options in Prelude Therapeutics Inc. as part of an equity compensation award.

Summary

• Director Victor Sandor received a grant of 38,000 stock options on June 9, 2026.
• The options have an exercise price of $3.94 per share.
• The options are set to expire on June 8, 2036.
• Vesting occurs on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the director.

Future Outlook

The options vest on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for small-cap biotechnology companies.
• The use of time-based vesting is a common industry benchmark for director compensation.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options upon the next annual stockholder meeting or June 9, 2027.

Key Dates

Keywords

Prelude Therapeutics, PRLD, Form 4, Insider Trading, Stock Options, Director Compensation